Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.
By K. Boffard, B. Riou, B. Warren, P. I. T. Choong, S. Rizoli, R. Rossaint, M. Axelsen, Y. Kluger. Journal of Trauma, 2005
761 citations recorded by the source corpus.
Subfields: Critical Care and Intensive Care Medicine, Hematology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/762856d62b925a73b9dc3b084d47122653b21419
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Critical Care and Intensive Care Medicine
In Hematology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Causes of Death in U.S. Special Operations Forces in the Global War on Terrorism: 2001–2004 (2007, neutral): “IED 1201 (32) 16 (20) 14 ( 21 ) 2 (17) RPG 466 (12) 2 (2) 1 (1) 1 (8) Rockets/mortar attack 337 (9) 1 (1) 1 (1) 0 Other explosions 26 (1) 16 (20) 16 (23) 0”
- Management of bleeding following major trauma: an updated European guideline (2010, background): “A multi-centre, randomised, double-blind, placebo-controlled study examined the efficacy of rFVIIa in patients with blunt or penetrating trauma [316] and showed that patients with blunt trauma who survived for more than 48 hours, assigned to receive rFVIIa 200 μg/kg, after they had received eight un”
- Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis. (2008, background): “All current efforts to correct traumatic coagulopathy are currently directed at augmenting the clotting factor pathway, through the administration of fresh frozen plasma(9) or recombinant factor VIIa.(10) In theory, while patients are shocked and thrombomodulin is present in excess, thrombin that is”
- Acute Traumatic Coagulopathy: Initiated by Hypoperfusion: Modulated Through the Protein C Pathway? (2007, background): “Consistent with this concept, recombinant factor VIIa has recently been investigated as another therapy for traumatic coagulopathy.(6) Two recent studies have identified an acute coagulopathy that is present on arrival in the emergency department in approximately one quarter of major trauma patients”
- Management of bleeding and coagulopathy following major trauma: an updated European guideline (2013, background): “134) trauma [507] and showed that patients with blunt”
- The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition (2019, result): “In contrast, there were no significant effects in the penetrating trauma patients, although trends towards reduced RBC requirements and fewer massive transfusions were observed [716].”